×
Arcutis Biotherapeutics EBIT 2018-2024 | ARQT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Arcutis Biotherapeutics ebit from 2018 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Arcutis Biotherapeutics EBIT 2018-2024 | ARQT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Arcutis Biotherapeutics ebit from 2018 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$146.3B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$114.2B
Vertex Pharmaceuticals (VRTX)
$108.7B
CSL (CSLLY)
$83.4B
Regeneron Pharmaceuticals (REGN)
$74.9B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$38.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$26.8B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$20.5B
Biogen (BIIB)
$20.5B
Incyte (INCY)
$13.9B
Genmab (GMAB)
$13.8B
Genmab (GNMSF)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.4B
Moderna (MRNA)
$13.1B
Insmed (INSM)
$13B
Bio-Techne Corp (TECH)
$12B
BioMarin Pharmaceutical (BMRN)
$11.7B
Sarepta Therapeutics (SRPT)
$11.3B
Vaxcyte (PCVX)
$10.6B
QIAGEN (QGEN)
$10.5B
Exelixis (EXEL)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exact Sciences (EXAS)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$9B
Roivant Sciences (ROIV)
$8.1B